English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

160-W lithium triboride laser (LBO) photoselective vaporization of the prostate (PVP) are two of them. The bipolar device was recently introduced into the field of urology primarily for treating obstructive prostatic disease.7–9 Intraoperative blood loss was less with the bipolar device than with TURP.10 Bipolar TUEP was refined to enucleate prostate adenomas along the surgical capsule with the method just as holmium laser enucleation of the prostate (HoLEP), fragmenting prostate adenomas using the bipolar resection loop. This technique does not compromise the cost properties of the laser and requires no additional device to fragment the tissue. It has also proved to be a safe, technically feasible treatment for BPH,11,12 regardless of the size of the prostate.13 PVP has been shown to be as effective as TURP for managing bladder outlet obstruction, with less perioperative morbidity14,15 and independent of the prostate size. To improve vaporization efficiency, the PVP system was increased from 80 to 180-W. Although the efficiency of 160-W LBO PVP system in our department is lower than the 180-W PVP system typically used in the United States and Europe, it is effective and safe for treating BPH.16 Thus, we aimed to assess the safety and efficacy of bipolar TUEP compared with PVP for treating BPH >70 ml.

Bipolar transurethral enucleation of prostate versus photoselective vaporization for symptomatic benign prostatic hyperplasia (>70 ml)